Translating 5‐HT4receptor pharmacology
Open accessThe DOI matches its Crossref record.
Abstract
Since metoclopramide was first described (in 1964) there have been several attempts to develop compounds which retained gastrointestinal prokinetic activity (via 5‐HT 4 receptor activation) but without the limiting side effects associated with dopamine D 2 receptor antagonism. Early compounds (mosapride, cisapride, renzapride, tegaserod) were identified before several of the 5‐HT receptors were even described (including 5‐HT 4 and 5‐HT 2B), whereas prucalopride came later. Several compounds were hampered by non‐selectivity, introducing cardiac liability (cisapride: activity at human Ether‐a‐go‐go Related Gene) or potentially, a reduced intestinal prokinetic activity caused by activity at a second 5‐HT receptor (renzapride: antagonism at the 5‐HT 3 receptor; tegaserod: antagonism at the 5‐HT 2B receptor). Poor intrinsic activity at gastrointestinal 5‐HT 4 receptors has also been an issue (mosapride, tegaserod). Perhaps prucalopride has now achieved the profile of good selectivity of action and high intrinsic activity at intestinal 5‐HT 4 receptors, without clinically‐meaningful actions on 5‐HT 4 receptors in the heart. The progress of this compound for treatment of chronic constipation, as well as competitor molecules such as ATI‐7505 and TD‐5108, will now be followed with interest as each attempts to differentiate themselves from each other. Perhaps at last, 5‐HT 4 receptor agonists are being given the chance to show what they can do.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationSchmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70
Horn, C. C. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3985-y · Cited by 38
Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders
Sanger, G. J., Chang, L., Bountra, C., & Houghton, L. A. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10369922 · Cited by 17
“Despite the difficulties referred to above and consequent reduced interest in future development of other 5-HT3 receptor antagonists, significant progress has been achieved in bringing forward new 5- HT4 receptor agonists [Sanger, 2009].”
BackgroundSelf-citationPharmacologic treatments for gastroparesis
Camilleri, M., & Jencks, K. J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100019 · Cited by 14
Metadata
- Authors
- Sanger, G. J.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2009-11-10
- Volume
- 21
- Issue
- 12
- Pages
- 1235-1238
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W1522676737
- Cited by
- 54
- References
- 0
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating 5‐HT4receptor pharmacology. https://app.cochat.ai/papers/10.1111/j.1365-2982.2009.01425.x
- The paper
- Sanger, G. J. (2009). Translating 5‐HT4receptor pharmacology. Neurogastroenterology & Motility. https://doi.org/10.1111/j.1365-2982.2009.01425.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.